Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune, and neurodegenerative disorders... Show more
Get AI intraday signals
A.I. Advisor
published Earnings
VTYX is expected to report earnings to rise 41.03% to -45 cents per share on March 19
Q4'25
Est.
$-0.45
Q3'25
Beat
by $0.13
Q2'25
Beat
by $0.08
Q1'25
Beat
by $0.10
Q4'24
Beat
by $0.13
The last earnings report on November 07 showed earnings per share of -31 cents, beating the estimate of -44 cents. With 1.40M shares outstanding, the current market capitalization sits at 678.62M.
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. VTYX showed earnings on November 07, 2025. You can read more about the earnings report here.